Evidence map›Paper›PMID 38173458›Full record

ArticleIJU case reports2024

Cine magnetic resonance imaging predicts thrombus adhesion in metastatic renal cell carcinoma with an inferior vena cava tumor thrombus: A case of pathological complete response with pembrolizumab plus lenvatinib.

Takuto Hara, Junya Furukawa, Takahiro Tsutiya, Takayuki Kodama, Keiichiro Uehara, Tomoaki Terakawa, Kenichi Harada, Jun Teishima, Yuzo Nakano, Masato Fujisawa

Open access · goldAbstract readCase Reports
In one paragraph

Article in IJU case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Takuto HaraDepartment of Urology Kobe University Graduate School of Medicine Kobe Japan.ORCID https://orcid.org/0000-0003-4524-2815
Junya FurukawaDepartment of Urology Kobe University Graduate School of Medicine Kobe Japan.
Takahiro TsutiyaDepartment of Diagnostic Pathology Kobe University Graduate School of Medicine Kobe Japan.
Takayuki KodamaDepartment of Diagnostic Pathology Kobe University Graduate School of Medicine Kobe Japan.
Keiichiro UeharaDepartment of Diagnostic Pathology Kobe University Graduate School of Medicine Kobe Japan.
Tomoaki TerakawaDepartment of Urology Kobe University Graduate School of Medicine Kobe Japan.
Kenichi HaradaDepartment of Urology University of Occupational and Environmental Health Kitakyushu Japan.
Jun TeishimaDepartment of Urology Kobe University Graduate School of Medicine Kobe Japan.
Yuzo NakanoDepartment of Urology Kobe University Graduate School of Medicine Kobe Japan.
Masato FujisawaDepartment of Urology Kobe University Graduate School of Medicine Kobe Japan.
Kobe University · JPUniversity of Occupational and Environmental Health Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Renal cell carcinoma with an inferior vena cava tumor thrombus is a challenging disease that requires a multimodal treatment approach. Pembrolizumab plus lenvatinib has displayed promising efficacy in metastatic renal cell carcinoma. Case presentation: A 61-year-old man was diagnosed with metastatic renal cell carcinoma and a tumor thrombus adhering to the inferior vena cava wall by cine magnetic resonance imaging. After 6 months of pembrolizumab and lenvatinib therapy, tumor shrinkage was detected, excluding the advanced portion of the inferior vena cava thrombus, and nephrectomy and thrombectomy were performed. Adhesion of the tumor thrombus to the inferior vena cava wall was observed during surgery. Resection produced a remarkable pathological complete response with no viable cells in the resected specimens, including the thrombus site. Conclusion: This case highlights the potential of pembrolizumab plus lenvatinib for treating advanced renal cell carcinoma with an inferior vena cava thrombus and the utility of cine magnetic resonance imaging for evaluating thrombus adhesion to the inferior vena cava.

Indexed as

cine MRIlenvatinibpathological complete responsepembrolizumabrenal cell carcinoma

Identifiers

PMID38173458
PMCPMC10758900
OpenAlexW4388535994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.